Montclair, NJ, May 22, 2015 ― Andrew Kitchenman today reports in NJ Spotlight that the U.S. House of Representatives’ 21st Century Cures Act, which unanimously passed the House’s Energy and Commerce yesterday, is attracting bipartisan support — including from New Jersey sponsors Reps. Frank Pallone (D-6) and Leonard Lance (R-7) — and is drawing praise across the state’s research community, as well as its biotechnology and pharmaceutical industries.
Those interviewed by Kitchenman see the legislation’s goals of increasing medical research funding and speeding the approval of new drugs and medical devices as essential to promoting therapies that will serve patients and promote the state’s biotech and pharma companies.
HealthCare Institute of New Jersey (HINJ) President and Chief Executive Officer Dean Paranicas commended Congressmen Pallone and Lance, and said that the Cures 2015 bill is “vitally important to New Jersey’s life sciences community, but more importantly, to patients around the world.”
The bill “would accelerate the pace of discovering cures for some of the world’s most dreaded diseases,” Paranicas continued. “Much of that work would involve and take place right here in New Jersey, by New Jersey companies.”
Paranicas singled out the FDA Safety Over Sequestration (SOS) (H.R. 1078) provisions sponsored by Congressman Lance. “This means that new, lifesaving breakthroughs can be reviewed, approved, and delivered to patients as quickly, efficiently and safely as possible,” he said.
For Kitchenman’s complete NJ Spotlight story, click here.
Kitchenman can be followed on Twitter at @Kitchenman.